Novavax Offers U.S. a Fourth Strong Covid-19 Vaccine by BY CARL ZIMMER


The company’s large U.S. trial found an efficacy rate of about 90 percent. But at this point, the nation is awash in other shots.

Published: June 14, 2021 at 12:00PM

from NYT Health https://ift.tt/2U8zjPD